breast cancer

News

Enhertu cleared for NHS use via Cancer Drugs Fund

NICE has recommended the use of AstraZeneca and Daiichi Sankyo's Enhertu in draft guidance, the first time the drug has been commissioned in any European country.

News

Gilead scores US approval for breast cancer drug that wowed ...

Gilead’s $21 billion purchase of Immunomedics and its potential blockbuster Trodelvy continues to pay off, as the drug has now been approved by the FDA for triple-negative breast cancer.

News

NICE okays regular NHS funding for Novartis' breast cancer d...

NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients.

News

Filing beckons as Lynparza hits the mark in adjuvant breast ...

AstraZeneca’s PARP inhibitor Lynparza has shown a clinical benefit when given as an adjuvant for early breast cancer, according to the data monitoring body for the phase 3 OlympiA trial.

News

Radiology technician examens mammography test on location

MacroGenics' HER2 breast cancer drug Margenza approved in US

MacroGenics’ HER2-targeted breast cancer drug Margenza has been approved by the FDA, challenging several recently approved drugs with a narrow efficacy edge over Roche’s Herceptin in data g

News

Daiichi Sankyo, AZ close on EU approval of Enhertu for breas...

Daiichi Sankyo and AstraZeneca could be just weeks away from an EU approval for their antib

Enhertu cleared for NHS use via Cancer Drugs Fund

Gilead scores US approval for breast cancer drug that wowed ...

NICE okays regular NHS funding for Novartis' breast cancer d...

Filing beckons as Lynparza hits the mark in adjuvant breast ...

MacroGenics' HER2 breast cancer drug Margenza approved in US

Daiichi Sankyo, AZ close on EU approval of Enhertu for breas...

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

breast cancer

Editor's Picks